过去一年中添加的文章，按日期排序
The association between osimertinib and nutritional deficiency among patients with non-small cell lung cancer.
6 天前 - … EGFR-TKIs (afatinib, dacomitinib, erlotinib, gefitinib). The outcomes of interest
included … higher risk of iron deficiency in the osimertinib cohort. Consistent with this observation, …
included … higher risk of iron deficiency in the osimertinib cohort. Consistent with this observation, …
Associations of early adverse events with clinical outcomes in patients with NSCLC treated with EGFR tyrosine kinase inhibitors.
FJ Lin, WY Lin, CC Wang, JY Shih - 2024 - ascopubs.org
6 天前 - … This study examined the prognostic implications of these … Methods: A retrospective
cohort study was conducted, … included 1,605 patients on gefitinib, 848 on erlotinib, and 1,236 …
cohort study was conducted, … included 1,605 patients on gefitinib, 848 on erlotinib, and 1,236 …
Reduced Risk of Incident Chronic Obstructive Pulmonary Disease Following EGFR-targeted Therapies in Patients With Lung Cancer
SYE Chan, PC Huang, KSK Ma - C46. CLINICAL AND …, 2024 - atsjournals.org
34 天前 - … cohort study was conducted in the United States from September 2018 to September
2023, investigating the connection between FDA-approved EGFRi - gefitinib, erlotinib, …
2023, investigating the connection between FDA-approved EGFRi - gefitinib, erlotinib, …
Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors …
K Uryu, Y Imamura, R Shimoyama, T Mase… - Cancer Chemotherapy …, 2024 - Springer
57 天前 - … survival outcomes compared to that of gefitinib and erlotinib in the FLAURA trial and
is … significant for gefitinib and osimertinib. Previous retrospective and cohort studies have …
is … significant for gefitinib and osimertinib. Previous retrospective and cohort studies have …
New-onset keratitis associated with epidermal growth factor receptor-based targeted therapies in Han Chinese patients with lung cancer: A multi-center cohort study
77 天前 - … When comparing gefitinib and erlotinib, the latter is … present study, which showed
that erlotinib, but not gefitinib, … In a meta-analysis, the incidence of erlotinib-induced ocular …
that erlotinib, but not gefitinib, … In a meta-analysis, the incidence of erlotinib-induced ocular …
[HTML][HTML] Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase …
78 天前 - … EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib (7). These agents, …
studied 119 patients in the pemetrexed-platinum cohort and 311 patients in the platinum cohort …
studied 119 patients in the pemetrexed-platinum cohort and 311 patients in the platinum cohort …
Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer
H Bai, Y Zhou, W Liu, W Xu, L Cheng, Y Huo, H Ji… - Heliyon, 2024 - cell.com
91 天前 - … Representative drugs like gefitinib and erlotinib have demonstrated enhanced …
The mPFS for gefitinib was 22.2 months, which was longer than icotinib and erlotinib cohorts, …
The mPFS for gefitinib was 22.2 months, which was longer than icotinib and erlotinib cohorts, …
242P Prognostic role of tumor microenvironment features in advanced non-small cell lung cancer molecular subtypes: A multicentric, retrospective study
L Zullo, A Marinello, MR Ghigna, G De Maglio… - ESMO Open, 2024 - esmoopen.com
95 天前 - … In EGFR+, 206 pts were analyzed for OS: 67 had first line osimertinib, 115
gefitinib/erlotinib, and 24 chemotherapy (CT). Median age was 66 (IQR 58-74), 145 (70%) were …
gefitinib/erlotinib, and 24 chemotherapy (CT). Median age was 66 (IQR 58-74), 145 (70%) were …
[PDF][PDF] European Society of Medical Oncology (ESMO) guidelines for oncogene-addicted metastatic non-small cell lung cancer (NSCLC): a personalized treatment for …
G Suay, F Aparisi, O Juan-Vidal - Chinese Clinical Oncology, 2024 - cdn.amegroups.cn
105 天前 - … gefitinib and erlotinib in first-line setting. However, no direct comparison was done
… difference between the ICI cohort and the control group. KEYNOTE-789 (17) was negative …
… difference between the ICI cohort and the control group. KEYNOTE-789 (17) was negative …
[PDF][PDF] Keratin gene signature expression drives epithelial-mesenchymal transition through enhanced TGF-β signaling pathway activation and correlates with adverse …
G Li, J Guo, Y Mou, Q Luo, X Wang, W Xue, T Hou… - Heliyon, 2024 - cell.com
140 天前 - … gefitinib, erlotinib, lapatinib, 55 and trametinib, in comparison to KGS-low cells.
Conclusion: This study … is that the findings ideally require validation in a broader cohort of LUAD …
Conclusion: This study … is that the findings ideally require validation in a broader cohort of LUAD …